(function(){ var content_array=["
關于<\/b>TVM Capital Life Science <\/b><\/p> \n
TVM Capital Life Science為北美和歐盟的國際生物制藥、醫療技術和診斷公司提供風險投資。TVM采用雙管齊下的策略,主要關注早期和晚期投資。<\/p> \n
www.tvm-lifescience.com<\/a><\/p> \n 聯系人:<\/b> <\/p> \n 媒體\/新聞: 投資者: 普通合伙人<\/b> 投資顧問 TVM Life Science Management GmbH 標志 - https:\/\/mma.prnasia.com\/media2\/1319854\/TVM_Capital_Life_Science_Logo.jpg?p=medium600<\/a><\/p>"];
$("#dvExtra").html(content_array[0]);})();
TVM Capital Life Science<\/b>:<\/b> Stefan Fischer,執行合伙人(融資), TVM Capital Life Science,fischer@tvm-capital.com<\/a>,+49 89 998 992 36<\/p> \n
OCP Capital<\/b>:<\/b>創始人Joelle Wyser-Prattejoelle@ocpcap.com<\/a>,+1 914 441 3554<\/p> \n
TVM Life Science Innovation II (GP) S. à r.l.
8, Rue Lou Hemmer
L-1748, Senningerberg
Grand Duchy of Luxembourg<\/span> <\/p> \n
TVM Life Science Management Inc.
2 Place Alexis Nihon, Suite 902, Montréal, QC H3Z 1X5, Canada<\/span> <\/p> \n
Ottostrasse 4
80333 Munich<\/span>
Germany<\/span><\/p> \n